AxoGen Earnings Call Highlights Growth, Biologic Pivot

AxoGen ((AXGN)) has held its Q4 earnings call. Read on for the main highlights of the call.

AxoGen’s latest earnings call struck an optimistic tone, as management balanced strong revenue growth, a landmark FDA approval and a fortified balance sheet against temporary margin and cost pressures. Executives framed 2026 as an investment and transition year, but underscored that the company is already cash-flow positive and positioned for structurally higher profitability once its new biologic scales.

Revenue Growth Remains a Standout Driver

AxoGen delivered Q4 revenue of $59.9 million, up 21.3% year over year, capping a full-year tally of $225.2 million, up 20.2%. Growth was fueled by higher unit volumes, favorable mix and continuing adoption of Avance across its core surgical markets, reinforcing the company’s ability to capture share in nerve repair.

Profitability Metrics Move in the Right Direction

Full-year adjusted EBITDA climbed 41% to $27.9 million, lifting margin by 180 basis points to 12.4%. Adjusted net income more than doubled to $14.4 million, or $0.29 per share, from $5.9 million, or $0.13 per share, signaling better operating leverage despite heavier spending.

Capital Raise Cleans Up the Balance Sheet

The company executed an upsized public offering in January, generating $133.3 million in net proceeds and using $69.7 million to retire its term loan. Year-end cash, equivalents, restricted cash and investments increased by $6 million to $45.5 million, leaving AxoGen with a simpler capital structure and more flexibility to fund growth.

FDA BLA Approval Positions Avance as a Category Leader

In December, the FDA granted BLA approval for Avance, the first and only approved biologic for peripheral nerve discontinuities, with 12 years of market exclusivity. Management emphasized that this milestone should cement Avance as the reference biologic, strengthen payer discussions and support prioritized clinical studies to expand its standard-of-care role.

Sales Force Expansion Underpins Commercial Push

AxoGen continued to scale its commercial footprint, adding 10 representatives in Breast to end the year at 21 and 12 in Extremities to reach 117. The company also added field managers and development staff in Oral Maxillofacial & Head & Neck and Prostate, with plans to grow Breast to roughly 30 reps and Extremities to about 130 reps in 2026.

Core Markets Show Momentum as Prostate Foundations Build

Management cited double-digit growth across Extremities, Oral Maxillofacial & Head & Neck and Breast, with Breast highlighted as one of the fastest-growing opportunities. In prostate, more than 100 procedures have been completed at 10 sites and a standard surgical technique established, but the company views this as groundwork rather than a near-term revenue engine.

High-Potential Accounts and Surgeon Training Drive Upside

Roughly 61% of total revenue growth came from high-potential accounts, where average account productivity rose 21% and 131 additional surgeons became active. Training initiatives exceeded targets, including 170 surgeons trained in Extremities, underscoring a strategy focused on deepening penetration in top sites rather than broad but shallow coverage.

Cash Flow Positive with Ambitious 2026 Targets

AxoGen was cash-flow positive for full-year 2025 and guided to at least 18% revenue growth in 2026, implying revenue of at least $265.7 million. Management forecast a full-year gross margin of 74%–76%, in line with 2025, and expects to generate positive free cash flow in 2026 while still investing heavily in sales force expansion and surgeon training.

Gross Margin Dips on One-Time BLA-Related Costs

Q4 gross margin declined to 74.1% from 76.1% a year earlier, with full-year margin slipping to 74.3% from 75.8%. The company attributed the roughly 1.5–2 percentage point drag to $1.9 million in one-time costs associated with the Avance BLA approval, most of which were noncash and not expected to recur.

Operating Expenses Surge on Investments and Stock Grants

Operating expenses jumped to $54.2 million in Q4 from $35.6 million a year ago and to $175.2 million for the full year from $145.3 million. The quarter included $7.2 million of noncash, one-time stock-based compensation tied to the BLA, which management noted weighed on operating margins but reflects long-term incentive alignment.

R&D and G&A Spike as Growth Platforms Scale

R&D spending rose 83.9% year over year in Q4 to $12.4 million, reaching 20.7% of revenue versus 13.6%, as the company ramped clinical and development work around Avance and new indications. G&A grew 64.6% to $14.6 million in the quarter, or 24.4% of revenue, driven by higher investment and noncash items linked to the BLA milestone.

Quarterly Loss Highlights Near-Term Margin Pressure

The company posted a Q4 net loss of $13.2 million, or $0.28 per share, compared with net income of $0.5 million a year earlier, reflecting the step-up in spending and one-time items. Q4 adjusted EBITDA eased slightly to $6.5 million from $6.7 million, with margin slipping 270 basis points to 10.9% as costs outpaced revenue growth.

Biologic Transition Set to Temporarily Compress Margins

Management warned that the shift to selling the Avance Biologic starting in Q2 2026 will introduce product cost pressure and weigh on gross margins in the near term. The company expects Q2 to show the brunt of the margin impact, with improvements targeted in 2027 as manufacturing efficiencies and scale benefits are realized.

Payer Coverage Advancing but Still Incomplete

Commercial coverage improved by roughly 19.8 million additional covered lives in 2025, pushing overall coverage above 65%. However, about 35% of the market remains uncovered, and executives cautioned that the timing of further payer wins is uncertain, leaving some upside contingent on future reimbursement progress.

Prostate Revenue Contribution Likely Modest in 2026

While AxoGen is building a foundation in prostate with more than 100 procedures and a standardized technique, management tempered expectations for near-term revenue. They indicated that meaningful commercial contribution from prostate is unlikely in 2026 as the company waits for clearer clinical signals and broader adoption.

Heavy Sales & Marketing Spend to Support Future Growth

Sales and marketing expense rose to 45.4% of revenue in Q4 from 40.6% a year earlier, reflecting a high-intensity commercial strategy. Management framed this spending as necessary to scale high-potential accounts and new markets, acknowledging near-term margin pressure but targeting future productivity gains as the expanded field force matures.

Guidance Points to Strong Growth and Cash Discipline

For 2026, AxoGen guided to at least 18% revenue growth to $265.7 million or more, with gross margin of 74%–76% despite expected cost headwinds from Avance Biologic starting in Q2. The company plans to remain free-cash-flow positive while expanding its Breast and Extremities sales teams, focusing 2026 growth on high-potential accounts and aggressive surgeon training across core specialties.

AxoGen’s earnings call painted a picture of a company in investment mode, trading some short-term margin for long-term strategic advantage after securing a pivotal FDA approval. For investors, the key watchpoints will be execution on biologic transition, productivity from the expanded sales force and the pace of payer coverage gains, all against a backdrop of solid top-line momentum and improving cash generation.